Broad spectrum anti-viral therapeutics targeting sphingosine-1 phosphate metabolizing enzymes
Sphingosine 1-phospate metabolizing enzymes are involved in modulating cellular responses to a variety of viruses in human and veterinary applications. In animal studies, treatments have demonstrated successful recovery of 50 percent to 60 percent of treated animals in response to otherwise fatal infections when treatments were administered orally, intraperitoneally, or intranasally. Patents issued and pending.
Influenza virus continues to cause tremendous morbidity and mortality on an annual basis. While vaccines exist to help prevent infection, there are only a handful of drugs approved for treating the infected individual. Moreover, the virus has evolved, in many cases, to become resistant to these treatments. The current discovery identifies sphingosine-1-phosphate pathway as critical for virus replication. Blocking sphingosine kinase activity or over expressing sphingosine 1-phosphate lyase strongly inhibited virus propagation. Therefore, modulation of this pathway could lead to new points of pharmaceutical intervention.